Previous Article | Next Article ![]()
J Virol, March 1998, p. 2335-2340, Vol. 72, No. 3
Division of Biological Sciences, the
University of Montana, Missoula, Montana 598121;
Departments of Biochemistry and Radiation Oncology, Eccles
Institute of Human Genetics, University of Utah, Salt Lake City, Utah
841122; and
Georgia VA Research
Center for AIDS and HIV Infections and Department of Pediatrics,
Emory University School of Medicine, Decatur, Georgia
300333
Received 27 June 1997/Accepted 26 November 1997
Mutants of feline immunodeficiency virus (FIV) resistant to
(
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
A Novel Point Mutation at Position 156 of Reverse Transcriptase
from Feline Immunodeficiency Virus Confers Resistance to the
Combination of (
)-
-2',3'-Dideoxy-3'-Thiacytidine and
3'-Azido-3'-Deoxythymidine


)-
-2',3'-dideoxy-3'-thiacytidine (3TC) were selected by culturing virus in the presence of increasing stepwise concentrations of 3TC. Two
plaque-purified variants were isolated from the original mutant
population, and both of these mutants were resistant to 3TC.
Surprisingly, these mutants were also phenotypically resistant to
3'-azido-3'-deoxythymidine (AZT) and to the combination of 3TC and AZT.
Purified reverse transcriptase (RT) from one of these plaque-purified
mutants was resistant to the 5'-triphosphates of 3TC and AZT. DNA
sequence analysis of the RT-encoding region of the pol gene
amplified from the plaque-purified mutants revealed a Pro-to-Ser
mutation at position 156 of RT. A site-directed mutant of FIV
engineered to contain this Pro-156-Ser mutation was resistant to 3TC,
AZT, and the combination of 3TC and AZT, confirming the role of the
Pro-156-Ser mutation in the resistance of FIV to these two nucleoside
analogs. This represents the first report of a lentiviral mutant
resistant to the combination of AZT and 3TC due to a single, unique
point mutation.
*
Corresponding author. Present address: Center for
Comparative Medicine, University of California, Davis, CA 95616. Phone: (530) 752-3414. Fax: (530) 752-7914. E-mail:
twnorth{at}ucdavis.edu.
Present address: Departments of Biochemistry and Radiation
Oncology, Eccles Institute of Human Genetics, University of Utah, Salt
Lake City, UT 84112.
Present address: Bayer Corporation, Clayton, NC 27520.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»